WEBINAR ON DEMAND
Duration: 1 hour ​

HPV plays a key role in oropharyngeal cancer, causing an estimated 70% of the 20,839 cases diagnosed in the U.S. each year. It’s also a positive prognostic indicator, as patients with HPV+ OPSCC tend to have less aggressive forms of the disease.

However, pathologists have traditionally not had access to good prognostic biomarkers for HPV driven OPSCC. As a result, sponsors and CROs have had limited opportunities to leverage biomarker testing for candidate selection, measuring treatment response and detecting recurrence among HPV+ OPSCC patients.

cfHPV-DNA has recently emerged as a novel prognostic biomarker for HPV+ OPSCC, with the potential to transform clinical research and therapeutic development. In this webinar, you’ll learn:

• The historical limitations in biomarker testing for HPV driven OPSCC.
• The Real World Data behind cfHPV-DNA as a prognostic indicator HPV+ OPSCC.
• How sponsors and CROs can leverage cfHPV-DNA in drug development.

SPEAKERS

Nishant Agrawal, MD
Professor of Surgery, Co-Director, Head and Neck Surgical Oncology
Chief of Otolaryngology - Head and Neck Surgery
University of Chicago Medicine

Ari Rosenberg, MD
Assistant Professor of Medicine
University of Chicago Medicine

Anna Starus, PhD
Associate Director
Medical Affairs and Product Development
Sysmex Inostics Inc.

 Jonathan Craft
Associate Director
Translational Research and Product Design
Sysmex Inostics Inc.